Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.41 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6023818 | 1.00 | MAPK1 (0.41) | MAPK1MAP2K4MAPKAPK3MAPK6BTK | |
| SCHEMBL4084403 | 0.80 | LRRK2 (0.33) | TTKCYP3A4AURKBINCENPMAPK8 | |
| SCHEMBL6024086 | 0.80 | RXRA (0.39) | MAPK1 | |
| SCHEMBL6024082 | 0.80 | RXRA (0.39) | MAPK1 | |
| SCHEMBL4084104 | 0.79 | TTK (0.36) | TTKCYP3A4AURKBINCENPMAPK8 | |
| SCHEMBL4089658 | 0.76 | BTK (0.61) | MAPK1MAP2K4MAPKAPK3MAPK6BTK | |
| SCHEMBL4090271 | 0.73 | TTK (0.41) | MAPK1MAP2K4MAPKAPK3MAPK6TTK | |
| SCHEMBL4090306 | 0.73 | TTK (0.41) | MAPK1MAP2K4MAPKAPK3MAPK6TTK | |
| SCHEMBL4083908 | 0.73 | CHRNB2 (0.48) | — | |
| SCHEMBL4083912 | 0.73 | CHRNB2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | MAPK1 166/4885MAP2K4 357/4885MAPKAPK3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.